Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922997 | 0.90 | MEN1 (0.42) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL2246968 | 0.84 | NPC1 (0.41) | LMNA | |
| SCHEMBL5660237 | 0.83 | ALOX5 (0.36) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL13248366 | 0.82 | NPSR1 (0.45) | MAPTMEN1LMNAKMT2AKDM4E | |
| SCHEMBL3922996 | 0.81 | LTA4H (0.38) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL2995598 | 0.80 | USP30 (0.47) | YAP1GPR119ALDH1A1MAPTMEN1 | |
| SCHEMBL13248365 | 0.80 | MEN1 (0.56) | MAPTMEN1LMNAKMT2AKDM4E | |
| SCHEMBL2245019 | 0.79 | NPC1 (0.47) | LMNAKMT2A | |
| SCHEMBL2246935 | 0.78 | NPC1 (0.39) | LMNABTK | |
| SCHEMBL2248325 | 0.78 | NPC1 (0.39) | LMNABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729104-B2 | Diphenyl substituted alkanes as flap inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729104-B2 | Diphenyl substituted alkanes as flap inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110190346-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-1814877-B1 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | MERCK & CO INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190346-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | ALOX5, ALOX15, ALOX15B | YAP1 4039/4885PRMT5 1410/4885GPR119 919/4885 |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | ALOX5, ALOX15, ALOX15B | YAP1 4039/4885PRMT5 1410/4885GPR119 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.